NRx Pharmaceuticals achieves data-lock of Phase 2b/3 trial of NRX-101

NRx Pharmaceuticals announced that the company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101. With data-lock, as forecast in last week’s earnings call, the complete data set passed on for statistical analysis; top-line data release expected in April 2024. With positive data from this study and FDA comment, NRx becomes eligible to receive the balance of its first milestone (an additional $4M) from partners Alvogen and Lotus Pharmaceuticals. These partners would then be responsible for all future development costs in this indication. NRx retains rights for all other indications, including chronic pain and PTSD. NRx is then poised to receive $320M in further milestones along with mid-teen royalties on net sales.